Skip to content

Telix Pharmaceuticals Limited Price, Chart & Factor Exposure

Free Data & Analytics Access
Telix Pharmaceuticals Limited · E.TLX.NASDAQ · United States
Use symbol E.TLX.NASDAQ in our API & Excel add-in to retrieve this data ↓
9.51
(+0.03%)
? Live Prices updated every 5-seconds. Momentum Factor ranges from -100 to +100 and is the mean of four timeframe signals (1 Day, 1 Week, 1 Month, 3 Months), where each timeframe is +1 if return is above 0 and -1 otherwise. Trend Factor ranges from -100 to +100 and is the mean of eight signals across 1-month, 3-months, 6-months, and 1-year, using price vs moving average and moving average slope (+1 or -1). A rollover occurs when trend flips sign. Bubble Risk is the z-score of current price vs 1-year price: (Current Price - 250 trading days SMA) / (250 days price standard deviation). Values above +2.5 indicate overbought; below -2.5 oversold. Realized Volatility (20-days) is the standard deviation of daily returns over the past 20 trading days multiplied by sqrt(252).
Momentum -100%
Trend -100%
Bubble Risk LOW
Realised Volatility (20D) 53.57%

Telix Pharmaceuticals Limited Forecast

Telix Pharmaceuticals Limited short-term momentum is strongly negative (up over 0 of 4 look-backs: 5, 10, 20 and 30 trading days), a short-term SELL signal. The long-term trend is strongly negative (0 of 8 checks up: price above, and slope of, its 50-, 100-, 150- and 200-day averages), a long-term SELL signal. Based on 20-day realised volatility of 53.6% a year, a typical one-standard-deviation range is 8.7924–10.23 over a week, 8.0393–10.98 over a month and 4.4154–14.60 over a year. (Signals as of 1 Nov 2026.)

Telix Pharmaceuticals Limited Price Chart

MacroFinance.ai

Telix Pharmaceuticals Limited Factors

Test factors in Return analysis →
Market/MacroIndicatorNowChangeRange
Quantitative
Telix Pharmaceuticals Limited
Momentum (composite)
—
ⓘLatest reading of Momentum (composite).
Telix Pharmaceuticals Limited
Relative Volume (21d)
—
ⓘLatest reading of Relative Volume (21d).
Telix Pharmaceuticals Limited
Signal
0
ⓘLatest reading of Signal.
Teal = supportive for Telix Pharmaceuticals Limited, red = a headwind, grey = neutral. Hover or tap ⓘ for how each factor works and to see returns in similar conditions.

Research on Telix Pharmaceuticals Limited

Explore MacroFinance macro & markets research and analysis.

Browse all financial research →

Telix Pharmaceuticals Limited Trading Strategies

57 backtested tactical asset allocation strategies hold SPY (US market), the closest tradable exposure to Telix Pharmaceuticals Limited; 27 of them are invested now. Strategies currently invested are listed first.

Hypothetical backtests over each ETF's own history; past performance does not guarantee future results. Upgrade to see every strategy's allocation and performance.

From creators

See all 57 strategies holding SPY →

Statistical Distribution of Returns

Plus

How Telix Pharmaceuticals Limited’s returns are distributed — and how they change in a given market regime.

Regime filters

Market/Macro Indicator Criteria Value And (for Between) Action

No regime filter yet — the chart below shows every period. Add a factor condition, or pick a popular regime.

MacroFinance.ai
Full return statistics
Statistic All periods Matching
  Sharpe, maximum drawdown and the full percentile table are part of Plus. Unlock with Plus
Know how Telix Pharmaceuticals Limited behaves before the regime turns Plus unlocks the full return history, unlimited factor conditions, regime-versus-baseline statistics and export — on every market, stock, ETF and index.

About Telix Pharmaceuticals Limited (United States)

Telix Pharmaceuticals Limited is a listed security in the United States. This page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data (the last 10 years as CSV or JSON, no login).

Last updated: November 22, 2026

More on Talanx AG

Frequently asked questions

What is Telix Pharmaceuticals Limited?
Telix Pharmaceuticals Limited is a listed security in the United States. On MacroFinance its page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data.
What is the latest Telix Pharmaceuticals Limited price?
The latest close is 9.51 (1 Nov 2026), +0.03% on the day. The price at the top of the page refreshes during the trading day.
Is Telix Pharmaceuticals Limited in an uptrend?
As of 1 Nov 2026, short-term momentum is strongly negative (0 of 4 look-backs up: 5, 10, 20 and 30 trading days) and the long-term trend is strongly negative (0 of 8 checks up on its 50- to 200-day moving averages). Bullish when both are positive, bearish when both are negative.
How volatile is Telix Pharmaceuticals Limited?
20-day realised volatility is 53.6% a year (1 Nov 2026), which implies a typical one-standard-deviation move of about 15.5% over a month and 7.5% over a week.
What factors affect Telix Pharmaceuticals Limited?
The Factors section lists the signals, relative-value, risk-model and macro factors linked to Telix Pharmaceuticals Limited, grouped as Quantitative Factors, each with its latest reading. Some factors are open to everyone; the rest need a MacroFinance plan.
Which trading strategies trade Telix Pharmaceuticals Limited?
57 backtested tactical asset allocation strategies trade Telix Pharmaceuticals Limited through SPY; 27 of them hold it now. The Trading Strategies section lists them with their current weight, CAGR, Sharpe ratio and maximum drawdown.
How are Telix Pharmaceuticals Limited returns analysed?
The Statistical Distribution of Returns section shows the distribution of Telix Pharmaceuticals Limited daily, weekly, monthly, 2-month and 3-month returns with count, annualised average return, volatility, Sharpe ratio and maximum drawdown, and lets you filter the history by factor conditions, e.g. only periods when momentum was positive. A free account tests up to 2 factor conditions over the last 1 year of history; a Plus plan unlocks the full history, unlimited conditions, the regime statistics and the export.
Where can I download free Telix Pharmaceuticals Limited historical data?
In the Free historical data section of this page: the last 10 years of Telix Pharmaceuticals Limited daily closes as CSV or JSON, no login needed. A free account unlocks the full history, Excel and API access.

Free Telix Pharmaceuticals Limited historical data (last 10 years)

Browse or instantly download the last 10 years of Telix Pharmaceuticals Limited daily price history. A free account unlocks the full history, an Excel export with factors, and API access.

Get the data as
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_history&symbol=E.TLX.NASDAQ&format=csv&years=10
DownloadLast 10 years, no login.
DateClose
2026-11-208.37
2026-11-198.71
2026-11-188.96
2026-11-178.855
2026-11-168.92
2026-11-139.23
2026-11-129.36
2026-11-119.725
2026-11-109.45
2026-11-099.89
Loading last 10 years…
The table and downloads stop at 10 years. A free account unlocks the full history, the Excel add-in and API access.
Create free account

About this stock

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney cancer; TLX101, a systemic therapy for the treatment of glioblastoma; TLX66, a product candidate for bone marrow conditioning for hematopoietic stem cell transplant conditioning; and Illuccix and Gozellix for the treatment of prostate cancer. The company is also developing TLX592, a prostate cancer therapy candidate for targeted alpha therapy based on its proprietary RADmAb-engineered antibody technology; TLX252 for the treatment of patients with advanced metastatic kidney cancer; TLX400, a bladder fibroblast activation protein for treating various tumors; TLX102, a large amino acid transporter-targeting small molecule-based alpha therapy candidate for the treatment of glioblastoma and multiple myeloma; TLX300 for treating soft tissue sarcoma; and TLX090, a bone-seeking agent for bone metastases and pain palliation. In addition, it is developing BiPASS, which is in Phase 3 clinical trial for prostate cancer diagnosis; AlFluor, a novel PET radiochemistry solution; TLX250-Px, a PET diagnostic imaging agent; and TLX101-Px, a radiolabeled amino acid PET agent. It operates in Australia, Belgium, Canada, the United Kingdom, the United States, and internationally. The company has strategic collaboration with University Hospital Essen. The company was founded in 2015 and is headquartered in North Melbourne, Australia.